Probiotix Health PLC - Director/PDMR Shareholding
Announcement provided by
ProBiotix Health Plc · PBX30/05/2025 07:01
30 May 2025
ProBiotix Health plc
("ProBiotix Health" or the "Company" or, together with its subsidiary, the "Group")
Director/PDMR Shareholdings
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce that Directors and PDMRs of the Company have acquired a total of 549,082 ordinary shares of 0.05p each in the Company ("Ordinary Shares").
Following these acquisitions, the Directors of the Company are interested in Ordinary Shares as follows:
|
Name |
Number of Ordinary Shares acquired |
Shareholding |
% |
|
Adam Reynolds |
50,000 |
192,857 |
0.06 |
|
Steen Andersen |
125,450 |
125,450 |
0.04 |
|
Stephen O'Hara |
- |
6,131,450 |
3.88 |
|
Marco Caspani |
- |
- |
- |
|
Frederik Bruhn-Petersen* |
- |
3,000,000 |
1.90 |
*Frederik Bruhn-Petersen is also interested in the 33,160,000 Ordinary Shares, representing 20.97% of the Company's issued share capital, held by Holdingselskabet of 29. Juni 2010 Aps.
Further information about the acquisitions of Ordinary Shares by the Directors and PDMRs is set out in the table below.
For further information, please contact:
|
ProBiotix Health plc |
|
|
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations |
|
|
|
|
|
Peterhouse Capital Limited Aquis Corporate Adviser and Broker |
|
|
Mark Anwyl Duncan Vasey |
Tel: 020 7220 9793 |
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. |
||||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Adam Reynolds |
Steen Andersen |
Mark Collingbourne |
Michael Litichevski |
Mads Brandt |
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Chairman |
Chief Executive
|
Chief Finance Officer |
Vice President, Sales |
Head of Supply Chain |
|
b) |
Initial notification /Amendment |
Initial |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor |
|||||
|
a) |
Name |
ProBiotix Health plc |
||||
|
b) |
LEI |
98450048683CF0388C30 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 0.05p each
ISIN: GB00BLNBFR86 |
||||
|
b) |
Nature of the transactions |
Acquisition of Ordinary Shares |
||||
|
c) |
Price(s) and volume(s) |
50,000 Ordinary Shares at 7.88p per share |
125,450 Ordinary Shares at 7.83p per share
|
108,907 Ordinary Shares at 7.25p per share |
75,780 Ordinary Shares at 7.25p per share |
188,945 Ordinary Shares at 7.83p per share |
|
d) |
Aggregated information - Aggregated volume - Price |
n/a - single transaction |
n/a - single transaction |
n/a - single transaction |
n/a - single transaction |
n/a - single transaction |
|
e) |
Date of the transactions |
29 May 2025 |
||||
|
f) |
Place of the transactions |
Aquis Growth Market |
||||
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
